Scarica l'app Stockscreener
70.98
1.47%
-1.06
Dopo l'orario di chiusura:
70.98
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline - MSN
Stock Report: Is Halozyme Therapeutics Inc forming a breakout patternEarnings Miss & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Halozyme Therapeutics (NASDAQ:HALO) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Jupiter Asset Management Ltd. Purchases 129,971 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Reports Significant 2025 Growth - National Today
Halozyme Therapeutics Reports Q4 Earnings - National Today
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $90.00 - MarketBeat
Benchmark Raises Target Price for HALO, Maintains Buy Rating | H - GuruFocus
Demystifying Halozyme Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Benchmark raises Halozyme stock price target to $90 on strong results - Investing.com Nigeria
Benchmark raises Halozyme stock price target to $90 on strong results By Investing.com - Investing.com South Africa
Halozyme (HALO) loses 9% on weak earnings - MSN
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $75.00 at Wells Fargo & Company - MarketBeat
Wells Fargo Raises Price Target on Halozyme Therapeutics (HALO) to $75 | HALO Stock News - GuruFocus
Halozyme (HALO) Loses 9% on Weak Earnings - Finviz
Halozyme Therapeutics (NASDAQ:HALO) Trading Down 8.7% on Disappointing Earnings - Defense World
TD Cowen raises Halozyme stock price target on royalty growth By Investing.com - Investing.com Nigeria
Why Halozyme Therapeutics (HALO) Is Down 7.9% After Acquisition-Driven Q4 Loss And 2026 Outlook Reaffirmation - Yahoo Finance
Halozyme Earnings Call Highlights Royalty-Fueled Growth - TipRanks
Halozyme Therapeutics (HALO) Reports Q4 Earnings Miss - GuruFocus
Halozyme shares slide as surprise Q4 loss and acquisition-related charges overshadow revenue beat - Quiver Quantitative
Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8.7% Following Weak Earnings - MarketBeat
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues - Nasdaq
Is Halozyme Therapeutics (HALO) Stock Price Out Of Step With Recent Valuation Signals - Yahoo Finance
TD Cowen raises Halozyme stock price target on royalty growth - Investing.com South Africa
Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge (NASDAQ:HALO) - Seeking Alpha
Halozyme Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript - Insider Monkey
Halozyme Therapeutics, Inc. $HALO Shares Sold by Hodges Capital Management Inc. - MarketBeat
Halozyme Therapeutics Inc (HALO) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Decoding Halozyme Therapeutics Inc (HALO): A Strategic SWOT Insi - GuruFocus
Halozyme Therapeutics Q4 2025 Earnings Call Highlights - Intellectia AI
Halozyme Q4 2025 Earnings Surge: Royalty Revenue Soars 52% - AlphaStreet News
Halozyme Therapeutics Q4 Earnings Call Highlights - MarketBeat
Halozyme Therapeutics (HALO) Reports Robust Growth in 2025 Earni - GuruFocus
Halozyme Therapeutics (NASDAQ:HALO) Announces Quarterly Earnings Results, Misses Expectations By $2.16 EPS - MarketBeat
Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings - Yahoo! Finance Canada
Halozyme (HALO) Q4 2025 Earnings Call Transcript - The Globe and Mail
Halozyme 2025 Earnings: Revenue Up 51.6%, Guides for 2026 EPS of $8News and Statistics - IndexBox
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
HALO Reaffirms Strong FY26 Revenue and EBITDA Growth Forecast - GuruFocus
(HALO) Halozyme Expects Full Year 2026 Revenue Range $1.71B$1.81B, vs. FactSet Est of $1.76B - marketscreener.com
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales - Finviz
Earnings Flash (HALO) Halozyme Therapeutics Posts Q4 Revenue $451.8M, vs. FactSet Est of $435.7M - marketscreener.com
Earnings Flash (HALO) Halozyme Therapeutics Posts Q4 Adjusted Loss $0.24, vs. FactSet Est of $2.16 Income - marketscreener.com
Halozyme Therapeutics: Fourth Quarter Earnings Overview - Bitget
Halozyme shares fall 4% following surprise Q4 loss - Investing.com Australia
Halozyme Therapeutics: Q4 Earnings Snapshot - marketscreener.com
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE - PR Newswire
Halozyme earnings in focus: Can royalty momentum carry into 2026? By Investing.com - Investing.com Australia
Halozyme earnings in focus: Can royalty momentum carry into 2026? - Investing.com
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): A GARP Stock with Strong Growth and Reasonable Valuation - ChartMill
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Halozyme Therapeutics Q4 Earnings Preview - Intellectia AI
0.34%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):